To evaluate if the Fra-1-NA plus c-Fos-NA-treatment was triggering a systemic effect on tumor growth, assays were performed inoculating 4T1 cells into both flanks of each mouse and 10 days later, one of the two tumors generated was treated with the high dose protocol whereas the other was treated with vehicle. The gene discussed is FOS; the disease is neoplasm.